5 White-Hot Stocks Trading Under $10 to Buy Now Have Great Upside Potential

Corvus Pharmaceuticals

This micro-cap biotech company could have some massive upside potential for aggressive traders. Corvus Pharmaceuticals Inc. (NASDAQ: CRVS), a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.

The company’s lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase 1/1b clinical trial, that inhibits the production of adenosine and activate various immune cells, as well as Phase 3 clinical trial of CPI-006 for COVID-19.

Corvus Pharmaceuticals also develops CPI-818, a covalent inhibitor of ITK, which is in Phase 1/1b clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase 1b/2 clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells, and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis.

Jefferies has an $8 price target on Corvus Pharmaceuticals stock. The lower consensus target is $5.70, and shares closed trading on Friday at $3.10.

CTI BioPharma

This is another micro-cap biotech that is expected to post some very positive clinical results early next year. CTI BioPharma Corp. (NASDAQ: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers in the United States.

It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase 3 clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreements with Teva Pharmaceutical Industries.

The stock was hit hard when the company announced the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a baseline platelet count of <50 × 109/L. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to February 28, 2022.

Stifel remains very positive and has a $5.50 target price. The consensus target is even higher at $7.12. The shares were last seen Friday at $1.61 up almost 12%.

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.